Rachel Klemovitch, Assistant Editor07.09.24
The Medartis Board has appointed Matthias Schupp as CEO. Matthias will succeed Christoph Brönnimann, who announced his resignation earlier this year. Schupp will assume his position as CEO by the beginning of November.
Schupp has held various senior leadership roles in Europe and Latin America at Straumann Group over the last 17 years.
Marco Gadola, Chairman of Medartis, said: “Matthias is an exceptionally talented and dynamic leader with a track record of delivery, driving growth, and developing winning teams. He brings with him deep expertise in medical technology as well as strong experience in both developed and developing markets. I’d like to thank Christoph Brönnimann for his years of great service and for continuing to lead Medartis until Matthias joins us later this year, and wish him all the best on his next journey.”
In 2014, he assumed the role of SVP of LATAM at Straumann, and in 2015 he became CEO of Neodent, steering the LATAM region through ten years of significant growth and enabling Neodent to flourish into a leading global challenger brand. In 2016, Schupp was appointed Executive Management Board of Straumann.
Schupp began his career in 1986 with Merck KGaA and rose through country management to the position of Regional Manager in Latin America and the USA. He moved to Wella in 2000 as Managing Director of the business in Russia and became Managing Director of Professional Care Portugal in 2004, following the acquisition of Wella by P&G.
Matthias added: “I am delighted to have been appointed as CEO of Medartis. It is a business with an impressive track record, a leading portfolio, a talented team and an excellent reputation. I am convinced by the strength of the business as well as its growth potential and look forward to leading Medartis into the next phase of development.”